Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-PRECISION: Proteogenomic Screening for Targeted Therapies in Advanced Solid Tumors
NCT07891169Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Open-label trial of nesuparib, cisplatin and crizotinib in solid tumor (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Rate of Successful Identification of Actionable Therapeutic Targets at 3 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
nesuparibcisplatincrizotinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07891169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07891169.